ArticleMolecular genetics & genomic medicine2017
A molecular analysis of the
Article in Molecular genetics & genomic medicine, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
8 citing papers in PubMed, 15 citations in OpenAlex.
- GBA1 in Parkinson's disease: variant detection and pathogenicity scoring matters.BMC genomics · 2023Article
- Review
- Genetic variability and potential effects on clinical trial outcomes: perspectives in Parkinson's disease.Journal of medical genetics · 2020Article
- Screening of the glucocerebrosidase (GBA) gene in South Africans of African ancestry with Parkinson's disease.Neurobiology of aging · 2020Article
- The Role of Genetic Testing in the Clinical Practice and Research of Early-Onset Parkinsonian Disorders in a Hungarian Cohort: Increasing Challenge in Genetic Counselling, Improving Chances in Stratification for Clinical Trials.Frontiers in genetics · 2019Article
- Diagnostic methods for Lysosomal Storage Disease.Reports of biochemistry & molecular biology · 2019Article
- Integrated Genetic Analysis of Racial Differences of CommonFrontiers in molecular neuroscience · 2018Article
- The Association between E326K ofParkinson's disease · 2018Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 2 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundThe molecular basis of Parkinson's disease in South African population groups remains elusive. To date, substitutions in the
methodsParticipants were recruited from tertiary hospitals in the Gauteng Province in South Africa. All participants were screened for substitutions in
resultsOf 105 Caucasian Parkinson's disease participants (82.7% Afrikaner) with an average age of disease onset of 61.9 ± 12.2 years and 40 controls (age 73.4 ± 12.4 years) were included. Heterozygous
conclusionMild
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.